Erik Penser Bank has published a Q&A with Attana’s CEO and Head of Diagnostics
Earlier today, Erik Penser Bank published an interview with Attana’s CEO, Teodor Aastrup, and Head of Diagnostics, Samir Fostock, who answer questions from shareholders.
The interview, led by equity research analyst Johan Löchen, is held in Swedish and answers questions regarding:
- Why did Attana start a new business area within diagnostics?
- What is the current status of Attana Diagnostics?
- What is the product offering?
- What is the sales and marketing strategy?
- What does the regulatory plan look like?
- How does Attana’s technology differ from ELISA-based diagnostics?
The video is uploaded on Erik Penser Bank’s Youtube channel and can be accessed through this link: https://youtu.be/9fsHLVuTV-U
For more information, please contact:
Teodor Aastrup, CEO
+46 (0)8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact firstname.lastname@example.org